Grace, R. F., Glenthøj, A., Barcellini, W., Verhovsek, M., Rothman, J. A., Morado, M., … Al-Samkari, H. (2022). Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat. In Blood (Vol. 140, pp. 5313–5315). American Society of Hematology. https://doi.org/10.1182/blood-2022-169125

Grace, Rachael F., Andreas Glenthøj, Wilma Barcellini, Madeleine Verhovsek, Jennifer A. Rothman, Marta Morado, D Mark Layton, et al. “Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat.” In Blood, 140:5313–15. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-169125.

Grace RF, Glenthøj A, Barcellini W, Verhovsek M, Rothman JA, Morado M, et al. Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat. In: Blood. American Society of Hematology; 2022. p. 5313–5.

Grace, Rachael F., et al. “Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 5313–15. Crossref, doi:10.1182/blood-2022-169125.

Grace RF, Glenthøj A, Barcellini W, Verhovsek M, Rothman JA, Morado M, Layton DM, Andres O, Galactéros F, van Beers EJ, Onodera K, Viprakasit V, Chonat S, Judge MP, Kosinski PA, Hawkins P, Gheuens S, Xu E, McGee B, Beynon V, Al-Samkari H. Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat. Blood. American Society of Hematology; 2022. p. 5313–5315.